Release Date: October 15, 2009
KNOWLEDGE GAP ADDRESSED
Medication non-compliance for patients with epilepsy has been recognized as a significant problem for many years (Cramer et al., 2002; Hayes et al., 2007). The very significant risks associated with failure to take epilepsy medicines has been made very clear by a recent report (Faught et al., 2008) that demonstrated a significant risk for injury and death during periods of noncompliance. For reasons of patient well being and safety, physicians must be better able to recognize non-compliance and its associated risks so they can develop strategies to prevent this very significant problem.
This program is supported by an educational grant from GlaxoSmithKline
Epileptologists, general neurologists, nurses, pharmacists and other healthcare professionals involved in the care of patients with epilepsy.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Epilepsy Society (AES) and the Epilepsy Therapy Project. The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Epilepsy Society designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Edward H. Bertram, III, M.D.
Joyce A. Cramer, B.S.
Robert Fisher, M.D., Ph.D.
Joseph Sirven, M.D.,
POLICY ON DISCLOSURES
It is the policy of the AES to make disclosures of financial relationships of faculty, planners, and staff involved in the development of educational content transparent to learners. All faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. AES carefully reviews reported conflicts of interest (COI) and resolves those conflicts by having an independent reviewer from the Council on Education validate the content of all presentations for fair balance, scientific objectivity, and the absence of commercial bias. The American Epilepsy Society adheres to the ACCME’s Essential Areas and Elements regarding industry support of continuing medical education; disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.
Joyce A. Cramer, B.S.: Consulting/Advisory Board: Bial, Eisai, Cyberonics, Medtronic, Ortho-McNeil, Pfizer, Sepracor, UCB; Salary: Epilepsy Therapy Project
Robert Fisher, M.D., Ph.D.: Intellectual Property/Patent Holder: NeuroVista, IntelliVision; Consulting/Advisory Board: Jazz Pharmaceuticals; SONY
Fred A. Lado, M.D., Ph.D.: Consulting/Advisory Board: Accorda Therapuetics; Stock Ownership: Cree, Schlumberger
© 2013 Epilepsy.com/professionals. All rights reserved.